Evaluation of the pharmacokinetics and safety of single and multiple ceftaroline fosamil infusions in healthy Chinese and Western subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 8, 2015, Pages 681-691

  Yang, Li ^a   Sunzel, Maria ^b   Xu, Peng ^b   Edeki, Timi ^b   Wilson, David ^b   Li, Jianguo ^b   Li, Haiyan ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Ceftaroline; Ceftaroline fosamil; Pharmacokinetics; Safety

Indexed keywords

CEFTAROLINE FOSAMIL; PLACEBO; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PPI-0903;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANEMIA; AREA UNDER THE CURVE; BLISTER; CHINESE; CONFERENCE PAPER; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSGEUSIA; DYSPEPSIA; FAINTNESS; FATIGUE; FEMALE; FOLLICULITIS; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HUMAN EXPERIMENT; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; INJECTION SITE PHLEBITIS; INJECTION SITE REACTION; KIDNEY DISEASE; LEUKOCYTE COUNT; LEUKOPENIA; MACULOPAPULAR RASH; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MORNING DOSAGE; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NORMAL HUMAN; NOSE EDEMA; NOSE OBSTRUCTION; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRESYNCOPE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RENAL CLEARANCE; RHINORRHEA; SINGLE DRUG DOSE; SKIN EDEMA; SOMNOLENCE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; UROGENITAL TRACT DISEASE; URTICARIA; VOMITING; WESTERN HEMISPHERE; AFRICAN AMERICAN; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MODEL; BIOTRANSFORMATION; BLOOD; CAUCASIAN; CHINA; CLINICAL TRIAL; COMPARATIVE STUDY; CULTURAL ANTHROPOLOGY; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; RISK ASSESSMENT; URINE; YOUNG ADULT;

ADULT; AFRICAN AMERICANS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOTRANSFORMATION; CEPHALOSPORINS; CHINA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; RISK ASSESSMENT; WESTERN WORLD; YOUNG ADULT;

EID: 84941067140     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202343     Document Type: Conference Paper

References (19)

1. AstraZeneca AB. ZINFORO™ 600 mg powder for concentrate for solution for infusion: Summary of product characteristics. Available from: http://www. ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/002252/ WC500132586.pdf. [Accessed 2015 March 27].
2. Forest Pharmaceuticals Inc. Teflaro® (ceftaroline fosamil) injection for intravenous (IV) use: US prescribing information. Available from: http://pi. actavis. com/data
3. Riccobene T, Jakate A, Rank D. A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis. J Clin Pharmacol. 2014; 54: 742-752. CrossRef PubMed
4. Van Wart SA, Forrest A, Khariton T, Rubino CM, Bhavnani SM, Reynolds DK, Riccobene T, Ambrose PG. Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. J Clin Pharmacol. 2013; 53: 1155-1167. PubMed
5. Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother. 2006; 50: 1376-1383. CrossRef
6. Erratum in: Antimicrob Agents Chemother. 2014; 58: 2489. PubMed
7. MacGowan A. Revisiting Beta-lactams - PK/PD improves dosing of old antibiotics. Curr Opin Pharmacol. 2011; 11: 470-476. CrossRef PubMed
8. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 1 investigators. CANVAS 1: the first Phase III, randomized, doubleblind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010; 65 (Suppl 4): iv41-iv51. CrossRef PubMed
9. Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T, et al; CANVAS 2 investigators. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010; 65 (Suppl 4): iv53-iv65. CrossRef PubMed
10. File TM Jr, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, Llorens L, Critchley IA, Thye DA; FOCUS 1 investigators. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011; 66 (Suppl 3): iii19-iii32. CrossRef PubMed
11. Low DE, File TM Jr, Eckburg PB, Talbot GH, David Friedland H, Lee J, Llorens L, Critchley IA, Thye DA; FOCUS 2 investigators. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011; 66 (Suppl 3): iii33- iii44. CrossRef PubMed
12. Zhong NS, Sun T, Zhuo C, D'Souza G, Lee SH, Lan NH, Chiang CH, Wilson D, Sun F, Iaconis J, Melnick D. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double- blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis. 2015; 15: 161-171. CrossRef PubMed
13. Dryden M, Wilson D, Iaconis J, Gonzalez J. A Phase III trial of ceftaroline fosamil 600 mg q8h versus vancomycin plus aztreonam in patients with cSSTI with systemic inflammatory response or underlying comorbidities. 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen, Denmark, 25-28 April 2015. Abstract O193. https://www.escmid. org/escmid-library/online-lecture-library/ material/?mid=22386.
14. Edeki T, Kujacic M, Broadhurst H, Li J, Sunzel M. Safety, local tolerability and pharmacokinetics of ceftaroline fosamil administered in a reduced infusion volume. Br J Clin Pharmacol. 2014; 78: 1291-1297. CrossRef PubMed
15. Riccobene TA, Su SF, Rank D. Single- and multipledose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam in healthy subjects. Antimicrob Agents Chemother. 2013; 57: 1496-1504. CrossRef PubMed
16. Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010; 65 (Suppl 4): iv67-iv71. CrossRef PubMed
17. Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 2011; 66 (Suppl 3): iii53-iii59. CrossRef PubMed
18. Huang HY, Luo XQ, Chan LS, Cao ZH, Sun XF, Xu JH. Cutaneous adverse drug reactions in a hospital-based Chinese population. Clin Exp Dermatol. 2011; 36: 135-141. CrossRef PubMed
19. Lin YF, Yang CH, Sindy H, Lin JY, Rosaline Hui CY, Tsai YC, Wu TS, Huang CT, Kao KC, Hu HC, Chiu CH, Hung SI, Chung WH. Severe cutaneous adverse reactions related to systemic antibiotics. Clin Infect Dis. 2014; 58: 1377-1385. CrossRef PubMed